MariTide
Maridebart cafraglutide / AMG 133 · GLP-1/GIP antibody-peptide conjugate (investigational)
What it is
Amgen's long-interval obesity candidate — an antibody-peptide conjugate notable for GIP receptor BLOCKADE (the opposite bet from tirzepatide's GIP activation). Currently in Phase 3.
What human evidence shows
Phase 2 data reported large weight loss with infrequent dosing; the same program made news for GI tolerability challenges that its trial design continues to work through. Published evidence remains incomplete while Phase 3 runs.
Risks
Trial-reported GI tolerability problems, and an antibody-conjugate's long half-life means a bad reaction persists for weeks, not days. Complex biologics of this class are beyond the manufacturing reach of unregulated labs — any purported product outside a registered study cannot be assumed to be the investigational drug.
Stacking interactions
Documented interactions with other things people research. A compound not listed here does not mean the combination is safe — only that no specific interaction is on file.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Combining two GLP-1 receptor agonists is not recommended: current GLP-1 labeling advises against concurrent use with another GLP-1 agonist, and stacking the same receptor action compounds GI and hypoglycaemia risk without a distinct mechanism.
Legal status
US: investigational, trial-access only.
Evidence base
early literature
Early human evidence: at least one human trial report, and not much beyond it.
- phase 3/4
- 0
- randomised
- 1
- reviews
- 0
- human trials
- 1
Counts are of published papers, not distinct trials, and measure how much research exists — not whether this works or is safe for you.
Research (6)
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and ObesityDiabetes Care · 2024
- Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 TrialN Engl J Med · 2025
- Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbiditiesPeptides · 2025
- Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in miceJCI Insight · 2024
- The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development ProgramsJ Clin Med · 2025
- One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapyAppetite · 2026
Turn MariTide into a plan that's yours
The info above is free. Membership makes it personal, the Coach answers questions about your exact stack, the Stack tracks it for you, and the Verified Sources shows you how to vet what you buy.
- ✓ AI Coach, ask anything about your stack. It does the dosing math, flags interactions, and tells you what to do next.
- ✓ Personal Stack, save your protocol, track it across devices, log doses, get a heads-up before a vial runs out.
- ✓ Verified Sources, the vetted reference for checking quality and sourcing, members only.
Cancel anytime · or save with $59.99/yr · Coach + Stack included